What is SimPL Serum?
Platelet lysate products are used as growth supplements for the culture of eukaryotic cells in vitro similar to the use of fetal bovine serum (FBS). Platelet lysates typically meet or exceed the performance of FBS due to their high growth factor content derived from platelet alpha-granules. SimPL is a platelet lysate product line derived from animal whole blood collected at approved abattoirs in the United States which drastically lowers cost compared to platelet lysates derived from human material. This allows for large batch sizes and a consistent supply of product for industry and research organizations.
For research and manufacturing use.
SimPL products have been designed to contain growth factor concentrations that allow it to match or exceed the growth rates of FBS supplemented media. Growth factors from platelet alpha-granules stimulate growth in a wide variety of mammalian cell types, allowing it to replace FBS as a ubiquitous supplement for growth medias used in cell culture and cell-based production systems.
Although the cost of SimPL Serum is less than half the average commercial price of FBS by volume, it has the potential to be orders of magnitude cheaper given typical cell expansion periods for industrial and academic use. When grown in SimPL Serum supplemented media, cell types such as 3T3-L1 fibroblasts and others yield approximately double the number of cells when compared to FBS media in a 3-day period. If these cells are expanded in each condition for 30 days, the number of cells yielded from SimPL Serum supplemented media would be more than 1,000-fold greater than from FBS supplemented media. Lower cost per volume and faster growth rates make SimPL Serum a vastly superior alternative to FBS for expanding cells in vitro.
SimPL Serum is tested to ensure the absence of detection for adventitious agents. Detection of viruses, bacteria, fungi, and mycoplasma is performed on our serum according to the 9CFR requirements for ingredients of animal origin used for the production of biologics (United States Code of Federal Regulations, Title 9, Part 113.53).